MedTrace Logo

Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)

NCT03689595 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 30000

Last updated 2026-05-07

No results posted yet for this study

Summary

The PROMISE Study aims to establish a prospective cohort of individuals with precursor conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma.

Conditions

Interventions

OTHER

Sample of Blood

Collection of blood sample from participants

Sponsors & Collaborators

Principal Investigators

  • Irene Ghobrial, MD · Dana-Farber Cancer Institute

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-10-31
Primary Completion
2033-10-31
Completion
2033-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03689595 on ClinicalTrials.gov